[225Ac]Ac-ETN029

· Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for [225Ac]Ac-ETN029, covering 2026-03-24 to 2026-03-24. Get the full timeline:

Most recent: Clinical Trial Update: Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors [Phase 1]